Jefferies Upgrades Relmada Therapeutics to Buy, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Andrew Tsai has upgraded Relmada Therapeutics from Hold to Buy and increased the price target from $3.5 to $13.
September 17, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has upgraded Relmada Therapeutics to Buy and significantly raised the price target from $3.5 to $13, indicating a positive outlook.
The upgrade from Hold to Buy by Jefferies, along with a substantial increase in the price target, suggests a strong positive sentiment from the analyst. This is likely to boost investor confidence and could lead to a short-term increase in RLMD's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100